Mr. Nicholas J. Oberhelman Profile

Nicholas J. Oberhelman

at Stanford Univ

SPIE Involvement:

Author

Publications (3)

Proceedings Article | 4 March 2019 Presentation

fluorescence-guided surgery with panitumumab-IRDye800 and cetuximab-IRDye800 in glioblastoma patients (Conference Presentation)

Quan Zhou, Sarah Miller, Nynke van den Berg, Guolan Lu, Hannes Vogel, Romain Cayrol, Nicholas Oberhelman, Stefania Chirita, Stan van Keulen, Gerald Grant, Gordon Li, Eben Rosenthal

Proceedings Volume 10862, 108620Y (2019) https://doi.org/10.1117/12.2510366

KEYWORDS: Tumors, Luminescence, Tissues, Surgery, Brain, Magnesium, Near infrared, Receptors, Monoclonal antibodies, Tissue optics

Read Abstract +

Introduction: Glioblastoma (GBM) is the most common and devastating primary brain tumor. The recurrence rate remains high with a median survival of 15 months. GBM’s infiltrative nature results in ill-defined margins that makes maximal tumor resection with minimal morbidity a challenge. Epidermal growth factor receptor (EGFR) is the most frequently amplified gene in GBM (35-45% of tumors) and is associated with overexpression in about 40-98% of cases, a characteristic of more aggressive phenotypes. We hypothesize that fluorescence labeled anti-EGFR monoclonal antibodies (mAb), panitumumab-IRDye800 (pan800) and cetuximab-IRDye800 (cet800), could be leveraged to enhance tumor contrast during surgical resection and improve patient outcome. Methods: 50mg fluorescently labeled corresponding study drugs, pan800 and cet800 respectively, were administered 1-2 days in glioblastoma patients with contrast enhancing (CE) tumors prior to surgery following 100 mg loading dose of unlabeled cetuximab or panitumumab. Near-infrared fluorescence imaging of tumor and histologically negative peri-tumoral tissue was performed intraoperatively and ex vivo. Fluorescence was measured as mean fluorescence intensity (MFI), and tumor-to-background ratios (TBRs) were calculated by comparing MFIs of tumor and histologically uninvolved tissue. Results: Despite heterogeneous drug uptake across all resected brain tissues, mean fluorescence intensity (MFI) correlated strongly (R^2=0.97) with tumor volume among histologically confirmed tumor tissues. The smallest detectable tumor size in a closed-field setting was 4.2 x 2.7 mm^2 (8.2 mg) for pan800 and 8.5 x 6.6 mm^2 (70mg) for cet800. Tumor tissues from pan800 infusion had significantly higher mean TBR (8.1 ± 4.6) than cet800 infused ones in intraoperative imaging (3.3 ± 2.7; P = 0.004). NIR fluorescence from both test drugs provided high contrast to identify as few as a cluster of (5 ± 1) tumor cells in macroscopic imaging of whole sections of paraffin embedded tissues. Sensitivity and specificity of MFI for viable tumor detection was calculated and fluorescence was found to be highly sensitive (64.4% for pan800, 73.0% for cet800) and specific (98.0% for pan800, 66.3% for cet800) for viable tumor tissue while normal peri-tumoral tissue showed minimal fluorescence. No related grade-2 adverse events were observed 30 days beyond the infusion of either study drugs. Conclusion: EGFR antibody based imaging for contrast-enhanced glioblastomas proved safe in human patients and specific intratumoral delivery of NIR fluorescence provided high optical contrast and resolution for intraoperative image-guided resection. Fully humanized panitumumab-IRDye800 demonstrated superior detection sensitivity and tumor specificity over the chimeric cetuximab-IRDye800.

Proceedings Article | 4 March 2019 Presentation

Predicting antibody penetration in a first-in-human clinical trial of head and neck cancers (Conference Presentation)

Guolan Lu, Shayan Fakurnejad, Brock Martin, Ashley Zhu, Nynke van den Berg, Stan van Keulen, Quan Zhou, Tarn Teraphongphom, Rebecca Gao, Nicholas Oberhelman, Stefania Chirita, Robert Erstey, Christina Kong, Dimitrios Colevas, Eben Rosenthal

Proceedings Volume 10859, 1085905 (2019) https://doi.org/10.1117/12.2513258

KEYWORDS: Tumors, Clinical trials, Head, Neck, Cancer, Image analysis, Tissues, Lymphatic system, Magnesium, Solids

Read Abstract +

Proceedings Article | 14 March 2018 Presentation

Panitumumab-IRDye800 for fluorescence-guidance based metastatic lymph node identification in patients with head and neck cancer (Conference Presentation)

Nynke van den Berg, Nutte Teraphongphom, Willemieke S. F. Tummers, Steven Hong, Guolan Lu, Adam Gomez , Brock Martin, Robert Ertsey, Nicholas Oberhelman, Christina Kong, Dimitros Colevas, Eben Rosenthal

Proceedings Volume 10478, 104780T (2018) https://doi.org/10.1117/12.2291298

KEYWORDS: Tumors, Luminescence, Lymphatic system, Head, Neck, Cancer, Surgery, Imaging systems, Receptors

Read Abstract +

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Keywords/Phrases

Search In:

Publication Years